Warning! GuruFocus detected
1 Severe warning sign
with NEUP.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Neuphoria Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US09063M2052
Share Class Description:
NEUP: Ordinary SharesDescription
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.73 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -12.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -18.2 | |||||
| 3-Year EPS without NRI Growth Rate | 1.5 | |||||
| 3-Year FCF Growth Rate | -4 | |||||
| 3-Year Book Growth Rate | 36 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.41 | |||||
| 9-Day RSI | 39.32 | |||||
| 14-Day RSI | 46.42 | |||||
| 3-1 Month Momentum % | 44.71 | |||||
| 6-1 Month Momentum % | 43.41 | |||||
| 12-1 Month Momentum % | -58.79 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.06 | |||||
| Quick Ratio | 2.06 | |||||
| Cash Ratio | 2.04 | |||||
| Days Sales Outstanding | 69.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 41.8 | |||||
| Shareholder Yield % | 2.78 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1050.53 | |||||
| Net Margin % | -414.48 | |||||
| FCF Margin % | -1175.11 | |||||
| ROE % | -16.14 | |||||
| ROA % | -11.55 | |||||
| ROIC % | -44.56 | |||||
| 3-Year ROIIC % | 292.25 | |||||
| ROC (Joel Greenblatt) % | -3262.3 | |||||
| ROCE % | -33.3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 12.26 | |||||
| PB Ratio | 0.61 | |||||
| Price-to-Tangible-Book | 40.95 | |||||
| EV-to-EBIT | -1.91 | |||||
| EV-to-Forward-EBIT | -0.51 | |||||
| EV-to-EBITDA | -2.01 | |||||
| EV-to-Forward-EBITDA | -0.51 | |||||
| EV-to-Revenue | 20.09 | |||||
| EV-to-Forward-Revenue | 0.05 | |||||
| EV-to-FCF | -1.71 | |||||
| Earnings Yield (Greenblatt) % | -52.36 | |||||
| FCF Yield % | -44.61 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NEUP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neuphoria Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.663 | ||
| EPS (TTM) ($) | -1.233 | ||
| Beta | 0.24 | ||
| 3-Year Sharpe Ratio | -0.68 | ||
| 3-Year Sortino Ratio | -0.92 | ||
| Volatility % | 105.16 | ||
| 14-Day RSI | 46.42 | ||
| 14-Day ATR ($) | 0.488059 | ||
| 20-Day SMA ($) | 5.318 | ||
| 12-1 Month Momentum % | -58.79 | ||
| 52-Week Range ($) | 2.124 - 15.24 | ||
| Shares Outstanding (Mil) | 1.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neuphoria Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neuphoria Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neuphoria Therapeutics Inc Frequently Asked Questions
What is Neuphoria Therapeutics Inc(NEUP)'s stock price today?
The current price of NEUP is $5.16. The 52 week high of NEUP is $15.24 and 52 week low is $2.12.
When is next earnings date of Neuphoria Therapeutics Inc(NEUP)?
The next earnings date of Neuphoria Therapeutics Inc(NEUP) is .
Does Neuphoria Therapeutics Inc(NEUP) pay dividends? If so, how much?
Neuphoria Therapeutics Inc(NEUP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers